Cancer immunotherapy can disable suppressive immune cells to aid tumor destruction news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Taha Merghoub and Jedd Wolchok of the Ludwig Center at Memorial Sloan Kettering Cancer Center (MSK) and former postdoc Roberta Zappasodi view more
Credit: Ludwig Cancer Research
FEBRUARY 15, 2021, NEW YORK - A Ludwig Cancer Research study has identified a novel mechanism by which a type of cancer immunotherapy known as CTLA-4 blockade can disable suppressive immune cells to aid the destruction of certain tumors. The tumors in question are relatively less reliant on burning sugar through a biochemical process known as glycolysis.
Researchers led by Taha Merghoub and Jedd Wolchok of the Ludwig Center at Memorial Sloan Kettering Cancer Center (MSK) and former postdoc Roberta Zappasodi now at Weill Cornell Medicine have discovered that in a mouse model of glycolysis-deficient tumors, CTLA-4 blockade does much more than stimulate cancer-targeting T cells of the immune system. In such tumors, anti-CTLA-4 therapy also destabilizes and reprograms regulatory T